证券代码：600812 证券简称：华北制药 编号：临 2025-017 华北制药股份有限公司 （一）审议通过《2025年第一季度报告》 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《2025 年第一季度报告》。 表决结果：同意 11 票； 反对 0 票； 弃权 0 票。 上述议案已经公司董事会审计委员会审议通过，并同意提交公司董事 会审议。 （二）审议通过《关于控股子公司定向减资的议案》 第十一届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届董事会第二十 次会议于 2025 年 4 月 21 日向全体董事、监事及公司高级管理人员以电子 邮件形式发出会议通知，以通讯方式于 2025 年 4 月 23 日召开。本次会议 应出席董事 11 名，实际出席董事 11 名。会议的召集、召开和表决程序符 合《公司法》等法律、行政法规、部门规章、规范性文件和《公司章程》 的规定 ...

证券代码：600812 股票简称：华北制药 编号：临 2025-019 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易简要内容：华北制药股份有限公司（以下简称"公司"）、公司所属控股子 公司华北制药华胜有限公司（以下简称"华胜公司"）与建信金融资产投资有限公司（以 下简称"建信投资"）拟签署《华北制药股份有限公司、华北制药华胜有限公司与建信 金融资产投资有限公司关于华北制药华胜有限公司之定向减资协议书》（以下简称"《定 向减资协议书》"），实施华胜公司定向减资，定向减资完成后建信投资退出华胜公司， 建信投资的持股比例由原来的 47.7389%降为 0%，减资对价拟定为 3 亿元（具体金额以 最终签署之协议为准）。 一、交易概述 2025 年 4 月 23 日，公司召开第十一届董事会第二十次会议，审议通 过了《关于控股子公司定向减资的议案》，同意公司、华胜公司与建信投 资签署《定向减资协议书》，实施华胜公司定向减资，定向减资完成后建 信投资退出华胜公司，建信投资的持股比例由原来的 47.7389%降为 0% ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 2,574,254,051.92, representing a 0.65% increase compared to CNY 2,557,512,113.04 in the same period last year[5]. - Net profit attributable to shareholders increased by 216.72% to CNY 57,491,586.04 from CNY 18,152,447.09 year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 376.62% to CNY 55,215,276.48 from CNY 11,584,706.31 in the previous year[5]. - Basic and diluted earnings per share rose by 209.09% to CNY 0.034 from CNY 0.011 in the same period last year[6]. - Operating profit for Q1 2025 increased to CNY 102,915,436.03, up from CNY 57,678,495.87 in Q1 2024, marking a growth of 78.3%[19]. - Net profit for Q1 2025 was CNY 103,152,262.47, compared to CNY 58,024,653.96 in Q1 2024, indicating a significant increase of 77.8%[19]. - The total comprehensive income for the first quarter of 2025 was CNY 76,665,384.87, compared to CNY 32,832,514.11 in the same quarter of 2024, reflecting a growth of 133.3%[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 21,994,031,603.41, a 2.43% increase from CNY 21,471,458,316.43 at the end of the previous year[6]. - Total assets as of March 31, 2025, were CNY 21,994,031,603.41, compared to CNY 21,471,458,316.43 at the end of 2024, an increase of 2.4%[15]. - Total liabilities increased to CNY 15,242,159,883.34 from CNY 14,796,845,228.85, reflecting a growth of 3.0%[16]. - Shareholders' equity as of March 31, 2025, was CNY 6,751,871,720.07, up from CNY 6,674,613,087.58, indicating an increase of 1.2%[16]. - The total assets of the company as of the end of the reporting period were CNY 20,766,375,602.41, compared to CNY 20,399,275,971.41 at the end of the previous period[26]. - The total liabilities increased to CNY 13,615,435,373.68 from CNY 13,257,882,326.66, indicating a rise of 2.7%[26]. Cash Flow - The net cash flow from operating activities decreased by 71.20% to CNY 163,313,819.39 from CNY 567,082,778.87 in the same period last year, primarily due to land compensation received in the previous year[5][8]. - Operating cash flow for Q1 2025 was CNY 163,313,819.39, a decrease of 71.2% from CNY 567,082,778.87 in Q1 2024[22]. - Cash flow from operating activities for Q1 2025 was CNY 233,541,416.19, down from CNY 468,135,883.93 in Q1 2024, a decrease of 50%[30]. - The cash flow from financing activities in Q1 2025 was CNY 12,963,768.54, contrasting with a negative cash flow of CNY -489,392,313.10 in Q1 2024[23]. - The net cash flow from financing activities was -$186,603,336.40, compared to -$457,540,488.63 previously[31]. Shareholder Information - The top three shareholders hold a combined 55% of the company's shares, with the largest being Jizhong Energy Co., Ltd. at 24.08%[10]. Operational Efficiency - The company implemented comprehensive budget management and lean management to enhance quality and efficiency, contributing to improved profitability[7]. - The company received government subsidies amounting to CNY 2,084,293.47, which are closely related to its normal business operations[7]. Inventory and Receivables - Accounts receivable increased to CNY 2,324,234,183.39 from CNY 2,049,376,568.87, representing a rise of 13.4%[14]. - Inventory decreased to CNY 2,395,392,879.99 from CNY 2,510,534,823.14, a decline of 4.6%[14]. - The company’s inventory decreased to CNY 976,648,688.09 as of March 31, 2025, from CNY 1,097,619,342.69 at the end of 2024, indicating a reduction of 11.0%[24]. Research and Development - Research and development expenses for Q1 2025 were CNY 30,287,934.42, significantly higher than CNY 16,960,117.65 in Q1 2024, marking an increase of 78.5%[27]. Accounting Standards - The company will not apply new accounting standards starting from 2025[32].

华北制药股份有限公司 关于冀中能源集团财务有限责任公司以未分配利润转增 注册资本暨关联交易的公告 证券代码：600812 股票简称：华北制药 编号：临 2025-020 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增资标的：冀中能源集团财务有限责任公司（以下简称"财务公司"）。 增资金额：人民币 2 亿元。 交易事项：增资前，财务公司注册资本 450,000.00 万元，冀中能源集团有限 责任公司（以下简称"冀中能源集团"）持有其 45%的股权，冀中能源股份有限公司（以 下简称"冀中能源"）持有其 35%的股权，华北制药股份有限公司（以下简称"公司" 或"华北制药"）持有其 20%的股权。本次增资财务公司拟以未分配利润 10 亿元按照各 股东持股比例同比例转增注册资本，其中公司以享有的未分配利润出资 2 亿元，增资完 成后，财务公司的股权结构不变。 财务公司与公司同属冀中能源集团的控股子公司，根据《上海证券交易所股票 上市规则》《公司章程》等相关规定，本次交易构成关联交易。 本次交易不构成《上市公司重大重组 ...

■■■■■600812■■■■2025■■■■■■■■25.74■■■■■■■0.65%■■■■■5749.16■■■■■■■216.72%■ ...

Core Insights - As of April 21, 2024, 2,246 companies have released their annual reports, with 1,197 reporting a year-on-year increase in net profit, while 1,049 reported a decline [1] - A total of 1,341 companies saw an increase in operating revenue, whereas 904 experienced a decrease [1] - Companies that reported simultaneous growth in both net profit and operating revenue include 940 firms, while 648 companies saw declines in both metrics [1] - Notably, 234 companies achieved a net profit growth rate exceeding 100%, with Zhengdan Co., Ltd. leading at an impressive 11,949.39% increase [1] Company Performance Summary - Zhengdan Co., Ltd. (300641) reported earnings per share of 2.35 yuan, with a net profit of 1,189.89 million yuan, reflecting a year-on-year increase of 11,949.39%, and operating revenue of 348.02 million yuan, up 126.31% [1] - Guangxi Energy (600310) reported earnings per share of 0.043 yuan, with a net profit of 62.99 million yuan, a significant increase of 3,704.04%, but a decline in operating revenue by 76.48% to 393.16 million yuan [1] - Siwei (688213) achieved earnings per share of 0.98 yuan, with a net profit of 39.27 million yuan, marking a 2,662.76% increase, and operating revenue of 596.81 million yuan, up 108.87% [1] - Other notable performers include Andis (600299) with a net profit of 120.43 million yuan (up 2,208.66%) and operating revenue of 1,553.43 million yuan (up 17.83%) [1] - Companies like Huabei Pharmaceutical (600812) and Jiangsu Suo (600746) also reported significant changes in their financial metrics, with varying trends in net profit and operating revenue [1][2]

Core Insights - As of April 17, 1695 companies have released their 2024 annual reports, with 947 reporting a year-on-year increase in net profit, while 748 reported a decline [1] - 1026 companies saw a year-on-year increase in operating revenue, whereas 669 experienced a decrease [1] - 750 companies reported simultaneous growth in both net profit and operating revenue, while 472 companies saw declines in both metrics [1] - A total of 180 companies achieved a doubling of their performance, with Zhengdan Co. leading with a staggering net profit growth of 11949.39% [1] Company Performance Summary - Zhengdan Co. (300641) reported earnings per share of 2.35 yuan, net profit of 118.99 million yuan, a year-on-year increase of 11949.39%, and operating revenue of 348.02 million yuan, up 126.31% [1] - Guangxi Energy (600310) had earnings per share of 0.043 yuan, net profit of 6.30 million yuan, a year-on-year increase of 3704.04%, but a significant decline in operating revenue by 76.48% to 393.16 million yuan [1] - North China Pharmaceutical (600812) reported earnings per share of 0.074 yuan, net profit of 12.70 million yuan, a year-on-year increase of 2496.80%, with operating revenue of 986.96 million yuan, down 2.48% [1] - Andisoo (600299) achieved earnings per share of 0.45 yuan, net profit of 120.43 million yuan, a year-on-year increase of 2208.66%, and operating revenue of 1.55 billion yuan, up 17.83% [1] - Other notable companies include Jiangsu Suopu (600746) with a net profit increase of 1029.62% and operating revenue growth of 18.43% [1] Additional Company Insights - Baoli Tianheng (688506) reported an impressive earnings per share of 9.25 yuan, net profit of 370.75 million yuan, and a remarkable year-on-year increase of 936.31% in net profit, with operating revenue of 582.27 million yuan [2] - Muyuan Foods (002714) achieved earnings per share of 3.30 yuan, net profit of 1.79 billion yuan, a year-on-year increase of 519.42%, and operating revenue of 13.79 billion yuan, up 24.43% [2] - Other companies like Xizi Clean Energy (002534) and Zhongchuan Defense (600685) reported varying performance metrics, with Xizi Clean Energy showing a decline in operating revenue by 20.33% [2]

Core Insights - As of April 15, 2024, 1,567 companies have released their annual reports, with 874 reporting a year-on-year increase in net profit, while 693 reported a decline [1] - A total of 942 companies saw an increase in operating revenue, whereas 625 experienced a decrease [1] - Companies that reported simultaneous growth in both net profit and operating revenue include Andisoo, among 686 others, while 437 companies saw declines in both metrics [1] Financial Performance Highlights - Guangxi Energy reported the highest net profit growth at 3,704.04%, with a net profit of 62.99 million and operating revenue of 393.16 million, which decreased by 76.48% [1] - North China Pharmaceutical achieved a net profit increase of 2,496.80%, with a net profit of 126.99 million and operating revenue of 986.96 million, down by 2.48% [1] - Andisoo's net profit rose by 2,208.66% to 1,204.33 million, with operating revenue increasing by 17.83% to 1,553.43 million [1] - Other notable performers include: - Shengyi Electronics: net profit up 1,428.23% to 331.97 million, operating revenue up 43.19% to 468.66 million [1] - Hualin Securities: net profit up 1,014.54% to 353.15 million, operating revenue up 41.35% to 143.48 million [1] Additional Company Insights - Companies with significant net profit increases also include: - Microelectronics: net profit up 815.36% to 5.21 million, operating revenue up 25.51% to 41.32 million [1] - Zhengzhou Coal: net profit up 783.88% to 282.66 million, operating revenue down by 2.74% to 420.49 million [1] - The report highlights a mix of performance across various sectors, indicating diverse trends in profitability and revenue growth among the listed companies [1][2]

重要内容提示： 被担保人名称：华北制药集团爱诺有限公司（以下简称"爱诺公司"） 系公司 全资子公司。 证券代码：600812 股票简称：华北制药 编号：临2025-016 华北制药股份有限公司 关于为下属子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次担保金额及已实际为其提供的担保余额：本次为爱诺公司提供连带责任保 证担保，担保金额为 4,000 万元。截至本公告披露日，公司已实际为爱诺公司提供的担 保余额为 12,000 万元（含本次）。 本次担保是否有反担保：否。 对外担保逾期的累计数量：公司为石家庄焦化集团有限责任公司担保人民币 9,000 万元，截至公告日该借款已逾期。 一、担保情况概述 近日，华北制药股份有限公司（以下简称"公司"）与中国农业银行 股份有限公司石家庄广安支行（以下简称"农行广安支行"）签订了《保 证合同》，为爱诺公司开展的流动资金借款业务提供连带责任保证担保。 单位：万元 | 序 | 被担保对 | | | | 本次提供担保前 | | 本次提供担保后 | | | --- | - ...

3月27日，华北制药（600812）(600812.SH，股价6.58元，市值112.9亿元)发布2024年年报，公司实现营 业收入98.70亿元，同比减少2.48%；归属于上市公司股东的净利润1.27亿元，同比增长2496.80%。 对于净利润的提升，华北制药表示，是公司通过调整产品结构，加强采购管理，降低采购成本，推行精 益管理，深挖成本费用管控等措施实现的。 对此，华北制药表示，公司聚焦主业，主动压减部分低毛利物流业务；心脑血管类产品的收入增加主要 源于苯磺酸左氨氯地平片第八批国采执标销量增加，神经、血液系统用药产品的收入增长主要源于甲钴 胺片国采执标区域增加、腺苷钴胺片主要销区收入较上年同期增加。 《每日经济新闻》记者注意到，华北制药是"医药集采大户"，尽管公司曾因"断供"集采被取消过2021年 8月11日至2022年5月10日期间参与国家集采的申报资格，但这没有动摇公司在国家组织药品集中带量采 购(简称"国采")中的地位，集采药品放量仍是华北制药主要的业绩驱动因素。 例如，在去年12月开标的"第十批国采"中，华北制药的注射用青霉素钠等4个品种全部成功中选。2024 年，公司抓好中选品种的增量增收，国 ...